Drugs / SH003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04360317 | Jun 2020 → May 2021 | cancer | Kyunghee University Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT03081819 | Mar 2017 → Apr 2019 | cancer | Kyunghee University Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SH003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03081819 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “a novel herbal medicine containing Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii.” PMID 32186413 ↗ Jan 2020 |
| Route | Oral | “participants will be divided into 3 groups based on SH003 daily dose (2400, 3600, and 4800 mg); the medication will be taken orally for 21 days.” PMID 32957363 ↗ Sep 2020 |